e-learning
resources
London 2016
Sunday, 04.09.2016
Molecular targets in pulmonary disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Are Vitamin D receptor genetic polymorphisms associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer?
Sonia Toujani Chekki (Tunis, Tunisia), Sonia Toujani Chekki, Jouda Cherif, Wajih Kaabachi, Houda Snene, Meriem Mjid, Yacine Ouhachi, Nozha Ben Salah, Bechir Louzir, Nadia Mehiri, Kamel Hamzaoui, Majed Beji
Source:
International Congress 2016 – Molecular targets in pulmonary disease
Session:
Molecular targets in pulmonary disease
Session type:
Thematic Poster
Number:
888
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Sonia Toujani Chekki (Tunis, Tunisia), Sonia Toujani Chekki, Jouda Cherif, Wajih Kaabachi, Houda Snene, Meriem Mjid, Yacine Ouhachi, Nozha Ben Salah, Bechir Louzir, Nadia Mehiri, Kamel Hamzaoui, Majed Beji. Are Vitamin D receptor genetic polymorphisms associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer?. Eur Respir J 2016; 48: Suppl. 60, 888
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer?
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Does consolidation chemotherapy improves survival for locally advanced non-small-cell lung cancer patients receiving concurrent chemoradiotherapy?
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
A polymorphism, which exists intronic lesion of SLC5A10, affects DRG2 expression and survival outcome of early-stage non-small cell lung cancer
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
The effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Loss of heterozygosity of PTEN in patients with non-small cell lung cancer treated and not treated with neoadjuvant chemotherapy
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007
Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
The prognostic significance of thrombocytopenia during chemotherapy in patients with advanced non-small cell lung cancer
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC)
Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up
Year: 2016
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
Changes in lymphocyte subgroups of non-small cell lung cancer patients during chemotherapy
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Reduction of peak oxygen consumption in patients with non-small cell lung cancer treated with neoadjuvant chemotherapy
Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts
Year: 2013
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Adrenalectomy for isolated lesions in operable patients with non-small-cell lung cancer
Source: International Congress 2016 – Special issues in thoracic surgery
Year: 2016
High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept